The Motley Fool
Published May 18, 2019 13:53
Updated May 18, 2019 14:06
Now that marijuana stocks have somewhat stabilized, it’s time for investors to take a good look at where they should put their next dollars.
Of the top tier marijuana stocks out there, it’s pretty much impossible to argue that Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) isn’t number one. But that doesn’t necessarily mean you should buy it at any moment.
This industry is still volatile, and even if Canopy Growth is set to explode, investors need to be mindful of investing at the right time to make the most of their investment.
Bearish view Canopy Growth has a lot to prove in the next while to show investors that it can keep up the hype. The company seemed to be making announcement after announcement that sent shares through the roof, but then that all suddenly stopped.
Meanwhile, investors were left realizing that all these announcements were simply the company spending money. Of course, that money is toward investing in the company’s future, but it’s hard to convince investors to buy more when the company just isn’t producing that record-breaking share growth of last summer.
This has some analysts believing canopy is in for a huge writedown. In fact, analysts’ predictions range widely, saying the stock could sink to $40 per share or rise to as much as $100 per share in the next 12 months.
Bullish view While the announcements and excitement may have subsided, the growth is still there for Canopy Growth. Recently, the company announced that net revenue grew 280% year over year . This is on top of the cash in pocket of $3.7 billion, which is mainly from the company’s investment from Constellation Brands (NYSE:STZ).
The company plans to continue its trend of spending to boost its market share, mostly through acquisitions like the one recently with Acreage Holdings. As this continues, and as the company’s reach expands, Canopy Growth really has set itself up to be the biggest and best long-term investment in the cannabis industry.
With 4.3 million square feet of licensed growing space and expansion plans still in place, this company definitely holds the title of the biggest. It’s also not just in Canada, but has expanded to medical cannabis markets across the world, and by entering the U.S. industry after hemp legalization.
Undervalued Right now, this stock is (finally) undervalued at the time of writing, trading at $61.25 per share. But not by much. Analysts believe it’s worth closer to $70 per share, and as I said, that could shrink or grow depending on what the company does in the next few months.
With its quarterly earnings report coming in June and cannabis-infused beverages on the table, there could be a huge amount of growth for this company in the next year. Also, as cultivation facilities come up and running, gross margins will skyrocket, bringing share prices even higher.
Bottom line This is a great stock, but I would wait until the next earnings report before buying. True, it’s undervalued, but in the last month alone it’s hit the low $50 per share range. Even if quarterly earnings are spectacular, it’s likely this stock will drop again to that level, which is when I would buy again.
It won’t be until production ramps up that this stock could soar once more, and maybe then it’ll hit that $100 per share mark.
Fool contributor Amy Legate-Wolfe owns shares of Canopy Growth.
The Motley Fool’s purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool Canada’s free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. Motley Fool Canada 2019
This Article Was First Published on The Motley Fool
Written By: The Motley Fool
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.